Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine th...
Saved in:
| Published in | BMC infectious diseases Vol. 20; no. 1; pp. 954 - 10 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
14.12.2020
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.
Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.
The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.
Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.
IRCT20180725040596N2 on 18 April 2020. |
|---|---|
| AbstractList | Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.
Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.
The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.
Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.
IRCT20180725040596N2 on 18 April 2020. Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease. Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05. The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19. Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design. Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.BACKGROUNDTreatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.METHODSUsing an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.RESULTSThe mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.CONCLUSIONOur findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.IRCT20180725040596N2 on 18 April 2020.TRIAL REGISTRATIONIRCT20180725040596N2 on 18 April 2020. Abstract Background Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease. Methods Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05. Results The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19. Conclusion Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design. Trial registration IRCT20180725040596N2 on 18 April 2020. Background Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease. Methods Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05. Results The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19. Conclusion Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design. Trial registration IRCT20180725040596N2 on 18 April 2020. Keywords: Arbidol, Corona virus, COVID-19, Efficacy Background Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease. Methods Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05. Results The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19. Conclusion Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design. Trial registration IRCT20180725040596N2 on 18 April 2020. |
| ArticleNumber | 954 |
| Audience | Academic |
| Author | Makiani, Mahin Jamshidi Nojomi, Marzieh Dehghan, Nasir Roham, Maryam Laali, Azadeh Yassin, Zeynab Navaei, Mehrnaz Keyvani, Hossein Ranjbar, Mitra |
| Author_xml | – sequence: 1 givenname: Marzieh surname: Nojomi fullname: Nojomi, Marzieh – sequence: 2 givenname: Zeynab surname: Yassin fullname: Yassin, Zeynab – sequence: 3 givenname: Hossein surname: Keyvani fullname: Keyvani, Hossein – sequence: 4 givenname: Mahin Jamshidi surname: Makiani fullname: Makiani, Mahin Jamshidi – sequence: 5 givenname: Maryam surname: Roham fullname: Roham, Maryam – sequence: 6 givenname: Azadeh surname: Laali fullname: Laali, Azadeh – sequence: 7 givenname: Nasir surname: Dehghan fullname: Dehghan, Nasir – sequence: 8 givenname: Mehrnaz surname: Navaei fullname: Navaei, Mehrnaz – sequence: 9 givenname: Mitra surname: Ranjbar fullname: Ranjbar, Mitra |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33317461$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt1r1TAYxotM3If-A15IwZvtojMfTdJ4IRyOUwuDAzp3G9J8HHNomy1pN91fv3RnznWISAMNb37Pk-TNs5_t9L43WfYagmMIK_ouQlQxXgAECkAor4rrZ9keLBksEMblzqP5brYf4wYAyCrEX2S7GGPISgr3svrEWqOG3Nt8ERqnfZsffu-cNb2_cuEo932-XJ3XHwvI3-cyD7LXvnM3RufK90PwbZumQ3CyfZk9t7KN5tX9_yA7-3RytvxSnK4-18vFaaEoZ0NBAa7SIFVDeYmoYQ2CjCBrFUeNJg2veCpCi3RFsFLAMI0Ys8pqjqEE-CCrt7bay424CK6T4Zfw0om7gg9rIcPgVGtE0yCGpMGUIVxSSiTmmqWiogyUFLPk9WHrdTE2ndHKpBvJdmY6X-ndD7H2V4IxXJYEJ4PDe4PgL0cTB9G5qEzbyt74MQpUMpBOTwBP6Nsn6MaPoU-dmigICYCk_EOtZbqA661P-6rJVCwoAQmCdDr38V-o9GnTufQuxrpUnwmOZoLp7czPYS3HGEX97ev_s6vzOfvmcQMfOvc7XwlAW0AFH2Mw9gGBQEwhFtsQixRicRdicZ1E1RORcoMc3BQ46dp_SW8BXxXvyQ |
| CitedBy_id | crossref_primary_10_2174_1389201024666230302113110 crossref_primary_10_3390_life12091456 crossref_primary_10_1016_j_biopha_2021_112518 crossref_primary_10_5808_gi_23005 crossref_primary_10_1002_jmv_27525 crossref_primary_10_3389_fphar_2021_683296 crossref_primary_10_1016_j_antiviral_2022_105514 crossref_primary_10_1002_hlca_202300208 crossref_primary_10_1016_j_pscia_2022_100002 crossref_primary_10_1016_j_ejmcr_2021_100013 crossref_primary_10_3389_fphar_2023_1053814 crossref_primary_10_3390_jof10070510 crossref_primary_10_4110_in_2021_21_e7 crossref_primary_10_1172_JCI170236 crossref_primary_10_1080_15257770_2021_1914851 crossref_primary_10_1360_SSV_2023_0121 crossref_primary_10_1016_j_ejphar_2024_176367 crossref_primary_10_3390_jpm12030349 crossref_primary_10_1002_bmb_21811 crossref_primary_10_1007_s12010_023_04439_4 crossref_primary_10_1016_j_antiviral_2023_105743 crossref_primary_10_3390_ijms23137365 crossref_primary_10_1007_s11427_022_2225_3 crossref_primary_10_1016_j_phymed_2021_153808 crossref_primary_10_3390_educsci11070347 crossref_primary_10_1186_s41043_024_00649_6 crossref_primary_10_1002_slct_202202097 crossref_primary_10_3390_math9222838 crossref_primary_10_3390_v13081665 crossref_primary_10_1161_STROKEAHA_122_040233 crossref_primary_10_2147_OPTH_S340576 crossref_primary_10_1038_s41392_021_00733_x crossref_primary_10_1021_acs_jcim_1c01061 crossref_primary_10_1016_j_biopha_2021_111966 crossref_primary_10_3390_ph14070664 crossref_primary_10_1016_j_gendis_2022_12_019 crossref_primary_10_29413_ABS_2021_6_4_7 crossref_primary_10_3390_molecules28186603 crossref_primary_10_3390_cimb44070208 crossref_primary_10_51847_IToVGoymnF crossref_primary_10_1016_j_molliq_2024_124074 crossref_primary_10_1139_cjc_2021_0247 crossref_primary_10_2174_1573405618666220509115914 crossref_primary_10_1002_med_21862 crossref_primary_10_1177_00469580211055630 crossref_primary_10_12998_wjcc_v9_i25_7350 crossref_primary_10_3389_fcimb_2024_1496176 crossref_primary_10_3390_app12020665 crossref_primary_10_4254_wjh_v13_i12_1850 crossref_primary_10_26442_00403660_2021_11_201206 crossref_primary_10_2478_acph_2022_0014 crossref_primary_10_1186_s12879_022_07068_0 crossref_primary_10_1080_17441692_2023_2272710 crossref_primary_10_3389_fcimb_2021_596201 crossref_primary_10_3390_medicina58091194 crossref_primary_10_1016_j_fmre_2021_01_013 crossref_primary_10_1016_j_imu_2021_100645 crossref_primary_10_3390_biologics1020016 crossref_primary_10_1177_2632010X241263054 crossref_primary_10_1016_j_jiph_2021_03_015 crossref_primary_10_1007_s10812_024_01797_7 crossref_primary_10_3389_fmicb_2022_845269 crossref_primary_10_2174_1567201819666221004094509 crossref_primary_10_3390_ph14080736 crossref_primary_10_1080_17476348_2021_1927719 crossref_primary_10_1149_1945_7111_acafa7 crossref_primary_10_1016_j_semerg_2021_06_009 crossref_primary_10_1007_s10787_022_00999_9 crossref_primary_10_3390_vaccines11010174 crossref_primary_10_1016_j_biopha_2023_114213 crossref_primary_10_2147_JMDH_S448786 crossref_primary_10_1007_s00210_024_03137_0 crossref_primary_10_1002_iid3_984 crossref_primary_10_1007_s00705_022_05368_z crossref_primary_10_1002_iid3_502 crossref_primary_10_3389_fonc_2022_837408 crossref_primary_10_1016_j_jmii_2021_05_011 crossref_primary_10_1186_s40545_023_00511_w crossref_primary_10_1186_s43094_021_00238_y crossref_primary_10_1007_s40199_024_00524_z crossref_primary_10_1016_j_humimm_2021_05_001 crossref_primary_10_1080_02648725_2023_2191081 crossref_primary_10_3390_cells10061412 crossref_primary_10_1016_j_snb_2024_136519 crossref_primary_10_1080_26895293_2021_1977186 crossref_primary_10_1016_j_jiph_2022_05_002 crossref_primary_10_3390_separations10070379 crossref_primary_10_1155_2023_1879554 crossref_primary_10_3390_ph14050411 crossref_primary_10_1186_s12985_023_01973_9 crossref_primary_10_3390_v13112306 crossref_primary_10_3389_fmolb_2021_671263 crossref_primary_10_3390_ijms25010354 crossref_primary_10_55531_2072_2354_2021_21_3_177_190 crossref_primary_10_1016_j_jiph_2021_05_009 crossref_primary_10_3389_fphar_2022_1056605 crossref_primary_10_1016_j_intimp_2021_108328 crossref_primary_10_3389_fimmu_2021_752227 crossref_primary_10_3389_fphar_2021_732403 crossref_primary_10_1186_s42269_022_00730_2 crossref_primary_10_18632_aging_202867 crossref_primary_10_52711_0974_360X_2024_00205 crossref_primary_10_1016_j_scitotenv_2024_177175 crossref_primary_10_2174_1566524021666210803154250 crossref_primary_10_31665_JFB_2021_16290 crossref_primary_10_1051_e3sconf_202129203092 crossref_primary_10_3390_molecules27238257 crossref_primary_10_1080_13543784_2022_2120801 crossref_primary_10_1186_s43556_021_00060_1 crossref_primary_10_37321_immunology_2022_3_4_05 crossref_primary_10_1016_j_ejmech_2024_117017 crossref_primary_10_1186_s43556_022_00078_z crossref_primary_10_37321_immunology_2022_3_4_04 crossref_primary_10_1016_j_crmicr_2023_100208 crossref_primary_10_1111_febs_16662 crossref_primary_10_22625_2072_6732_2023_15_1_48_54 crossref_primary_10_3892_mmr_2022_12779 crossref_primary_10_1002_jmv_27481 |
| Cites_doi | 10.1016/j.jinf.2020.03.060 10.1128/JVI.02077-15 10.2174/092986708784049658 10.1038/s41598-018-27224-4 10.3866/PKU.DXHX202002013 10.1016/j.jinf.2020.03.002 10.1016/j.jinf.2020.04.008 10.1101/2020.03.19.20038984 10.1016/j.ejmech.2020.112687 10.1016/j.bja.2020.07.001 10.1007/s11596-020-2203-3 10.4155/tde-2020-0035 10.1128/JVI.02185-18 10.1016/j.antiviral.2020.104787 10.5582/bst.2020.01047 10.1101/2020.04.11.20056523 10.1002/jmv.25358 10.1016/j.tmaid.2020.101615 10.1016/j.antiviral.2014.04.006 10.1148/radiol.2020200463 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
| Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12879-020-05698-w |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints (UHCL Subscription) Gale In Context: Science (UHCL Subscription) ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1471-2334 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_bb272ae367234665a39d7bb2c6704637 PMC7734453 A650501167 33317461 10_1186_s12879_020_05698_w |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | Iran China |
| GeographicLocations_xml | – name: Iran – name: China |
| GrantInformation_xml | – fundername: Iran University of Medical Sciences grantid: 17640 – fundername: ; grantid: 17640 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PMFND 3V. 7QL 7T2 7U9 7XB 8FK AZQEC C1K COVID DWQXO H94 K9. M7N PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c697t-603803858b69426e7b21752ffc92bd5b9896e71f2d853cc0e7d277fcfd931a03 |
| IEDL.DBID | M48 |
| ISSN | 1471-2334 |
| IngestDate | Wed Aug 27 01:13:17 EDT 2025 Thu Aug 21 13:45:36 EDT 2025 Tue Aug 19 12:36:05 EDT 2025 Fri Jul 25 21:26:48 EDT 2025 Tue Jun 17 21:26:17 EDT 2025 Tue Jun 10 20:45:12 EDT 2025 Fri Jun 27 04:03:31 EDT 2025 Fri Jun 27 04:37:19 EDT 2025 Thu Apr 03 07:04:38 EDT 2025 Tue Jul 01 01:57:46 EDT 2025 Thu Apr 24 23:03:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 Corona virus Efficacy Arbidol |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c697t-603803858b69426e7b21752ffc92bd5b9896e71f2d853cc0e7d277fcfd931a03 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/docview/2471150154?pq-origsite=%requestingapplication% |
| PMID | 33317461 |
| PQID | 2471150154 |
| PQPubID | 42582 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bb272ae367234665a39d7bb2c6704637 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7734453 proquest_miscellaneous_2470277509 proquest_journals_2471150154 gale_infotracmisc_A650501167 gale_infotracacademiconefile_A650501167 gale_incontextgauss_ISR_A650501167 gale_incontextgauss_IOV_A650501167 pubmed_primary_33317461 crossref_primary_10_1186_s12879_020_05698_w crossref_citationtrail_10_1186_s12879_020_05698_w |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-14 |
| PublicationDateYYYYMMDD | 2020-12-14 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2020 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | JN Zhang (5698_CR18) 2020; 40 5698_CR26 5698_CR25 MJ Campbell (5698_CR12) 2007 5698_CR2 5698_CR3 5698_CR5 H Amawi (5698_CR13) 2020; 11 5698_CR1 X Liu (5698_CR22) 2020; 81 5698_CR21 5698_CR6 5698_CR7 E-I Pécheur (5698_CR9) 2016; 90 5698_CR19 YS Boriskin (5698_CR8) 2008; 15 5698_CR14 Z Zhu (5698_CR20) 2020; 81 SL Fink (5698_CR15) 2018; 8 Y Xiao (5698_CR4) 2020; S1473–3099 IA Leneva (5698_CR16) 2019; 91 L Deng (5698_CR24) 2020; 81 LU Zheng (5698_CR10) 2020; 205 J Blaising (5698_CR17) 2014; 107 5698_CR11 K Xu (5698_CR23) 2020; 49 |
| References_xml | – volume: 81 start-page: e21 issue: 1 year: 2020 ident: 5698_CR20 publication-title: J Infect doi: 10.1016/j.jinf.2020.03.060 – volume: 90 start-page: 3086 year: 2016 ident: 5698_CR9 publication-title: J Virol doi: 10.1128/JVI.02077-15 – volume: 15 start-page: 997 year: 2008 ident: 5698_CR8 publication-title: Curr Med Chem doi: 10.2174/092986708784049658 – volume: 8 start-page: 8989 issue: 1 year: 2018 ident: 5698_CR15 publication-title: Sci Rep doi: 10.1038/s41598-018-27224-4 – volume: 49 start-page: 0 issue: 1 year: 2020 ident: 5698_CR23 publication-title: Zhejiang da xue bao Yi xue ban doi: 10.3866/PKU.DXHX202002013 – ident: 5698_CR1 – volume: 81 start-page: e1 issue: 1 year: 2020 ident: 5698_CR24 publication-title: J Infect doi: 10.1016/j.jinf.2020.03.002 – volume: 81 start-page: e95 issue: 1 year: 2020 ident: 5698_CR22 publication-title: J Infect doi: 10.1016/j.jinf.2020.04.008 – ident: 5698_CR3 – ident: 5698_CR26 – ident: 5698_CR19 doi: 10.1101/2020.03.19.20038984 – volume: 205 start-page: 112687 year: 2020 ident: 5698_CR10 publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2020.112687 – ident: 5698_CR21 doi: 10.1016/j.bja.2020.07.001 – volume: S1473–3099 start-page: 30152 issue: 20 year: 2020 ident: 5698_CR4 publication-title: Lancet Infect Dis – volume: 40 start-page: 480 issue: 3 year: 2020 ident: 5698_CR18 publication-title: Curr Med Sci doi: 10.1007/s11596-020-2203-3 – volume: 11 start-page: 245 issue: 4 year: 2020 ident: 5698_CR13 publication-title: Ther Deliv doi: 10.4155/tde-2020-0035 – ident: 5698_CR14 doi: 10.1128/JVI.02185-18 – ident: 5698_CR7 doi: 10.1016/j.antiviral.2020.104787 – ident: 5698_CR6 doi: 10.5582/bst.2020.01047 – ident: 5698_CR25 doi: 10.1101/2020.04.11.20056523 – start-page: 267 volume-title: Medical Statistics: A Textbook for the Health Sciences Wiley, 4th Edition year: 2007 ident: 5698_CR12 – volume: 91 start-page: 588 issue: 4 year: 2019 ident: 5698_CR16 publication-title: J Med Virol doi: 10.1002/jmv.25358 – ident: 5698_CR5 doi: 10.1016/j.tmaid.2020.101615 – ident: 5698_CR2 – volume: 107 start-page: 84 year: 2014 ident: 5698_CR17 publication-title: Antivir Res doi: 10.1016/j.antiviral.2014.04.006 – ident: 5698_CR11 doi: 10.1148/radiol.2020200463 |
| SSID | ssj0017829 |
| Score | 2.6023498 |
| Snippet | Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not... Background Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO)... Abstract Background Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 954 |
| SubjectTerms | Adult Aged Antiretroviral drugs Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs Arbidol Blood Cardiovascular disease Clinical trials Corona virus Coronaviruses Cough COVID-19 COVID-19 Drug Treatment Disease transmission Drug Combinations Dyspnea Efficacy FDA approval Female Fever Hospitalization Humans Hydroxychloroquine Hydroxychloroquine - therapeutic use Immunomodulators Independent variables Indoles - therapeutic use Lopinavir Lopinavir - therapeutic use Male Medical imaging Middle Aged Neutrophils Oxygen Oxygen content Pandemics Patients Pharmacology, Experimental Public health Regression analysis Respiration Ritonavir Ritonavir - therapeutic use SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Teaching hospitals Variance analysis Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA_SB_FFrJ9rq6wiqEjobpJNNr7VaukJtaBt6VvYfNmF627p3VnoX99JNnfcIuqLb0syC7uTSeY3zMwvCL1xzFTCG4qF1BIz3xRYh2Yf5gDJCaJ5bULv8OE3fnDCvp5VZ2tXfYWasIEeeFDcjtZEkMZRLghlnFcNlVbAoOEikF3FPnLwectgKuUPwO_JZYtMzXdmcAoLiUOoBA5f1vh65IYiW__vZ_KaUxoXTK55oP0H6H6Cjvnu8Mmb6I7rHqK7hyk5_ghNBibivPcgo1vbT_N3Jxetd13_q716n_ddvnd0OvmMS_kxb3JwUra_aG-czVO9-hQe4y0ej9Hx_pfjvQOcbkrAhksxx7ygdUzxaS7B5TqhIdKoiPdGEm0rLWsJg6UnFryzMYUTlghYIm8lLZuCPkEbXd-5ZyiHCKMxjeAAGwtGta2517qsvQVcVxDpMlQu9aZMYhEPl1lMVYwmaq4GXSvQtYq6VtcZ-rB653Lg0Pir9KewHCvJwH8dB8AqVLIK9S-ryNDrsJgqMFx0oYTmZ7OYzdTk6FTtAiatYvrpT0I_vo-E3iYh38OPmia1LYC6AnPWSHJ7JAn71Iynl4al0jkxUwSwAUBywLEZerWaDm-G2rfO9YsoExLtgOwy9HSww5VyKAX8x3iZITGy0JH2xjNdex5ZxIWgjFX0-f9Q9xa6R8LmKgku2TbamF8t3AsAa3P9Mu7LW2LPNdI priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3raxQxEA9aQQQRra_VKqsIKhK6m-wmG79IrZaeUAvalvsWNq-6cN2tt3cW_OudZHNnF7HfjmQCe5NkHpmZ3yD0yha65E5TzIUSuHB1hpUv9iksWHKcKFZpXzt88JXtHxdfpuU0Prj1Ma1yJRODoDad9m_k2wSkKBgvoPE_nP_EvmuUj67GFhrX0Q0PXeZTuvh07XDloP3EqlCmYts9yGIusHeYQO2LCl-MlFHA7P9XMl9STeO0yUt6aO8uuhMNyHRn2PF76JptN9HNgxgi30S3h4e4dKgvuo8mAz5x2jlYoxrTzdI3x2eNs233q5m_Tbs23T08mXzCuXif1imoLtOdNb-tSWMW-wx-ht4eD9DR3uej3X0c-ydgzQRfYJbRKgT-FBOgiC1X4H-UxDktiDKlEpWAwdwRAzpb68xyQzhsnDOC5nVGH6KNtmvtY5SC31HrmjMwJrOCKlMxp1ReOQPWXkaETVC-4qPUEVvct7iYyeBjVEwOvJfAexl4Ly8S9G695nxA1riS-qPfnjWlR8UOA938VMZLJpUinNSWMk5owVhZU2E4DGrGPTAaT9BLv7nS4160PrHmtF72vZwcnsgdsFTLEJT6H9H3byOi15HIdfBHdR2LGYBdHk9rRLk1ooTbq8fTq4Mmo_To5d-znqAX62m_0mfEtbZbBhoffgd7L0GPhnO5Zg6lYBUWLE8QH53YEffGM23zI2CLc06LoqRPrv6sp-gW8dcoJzgvttDGYr60z8A4W6jn4Qb-ARJZMzw priority: 102 providerName: ProQuest |
| Title | Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33317461 https://www.proquest.com/docview/2471150154 https://www.proquest.com/docview/2470277509 https://pubmed.ncbi.nlm.nih.gov/PMC7734453 https://doaj.org/article/bb272ae367234665a39d7bb2c6704637 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwELb2Ik37gngnMKqAkAChQGI7doyE0Fo2rUjdUNmmii9W7NijUpdAXxjw6zm7SVnExpeoss-Ver7L81zPvkPomaE65VaTiAslImrzOFLusg81wOQ4VizT7u7w4JAdnNCPo3S0hpp2R7UCZ1eGdq6f1Ml08vrn91_vweHfeYfP2JsZvGO5iFwgBHAusuhiHW0CMnHnqAP6N6sAaCiaizNXrttGW4QAolKWtHDKl_P_96V9CbXaJyovQdT-TXSj5pbh7tIYbqE1U95GW4M6e34H9ZelisPKgowaF9UkfHFyPramrH6Mpy_Dqgx7R6f9D1Ei3oZ5CChWVOfj36YI6wPtE_jo23zcRcf7e8e9g6hupRBpJvg8YjHJfA5QMQGYbLiCUCTF1mqBVZEqkQkYTCwuAL61jg0vMIc9tIUgSR6Te2ijrErzAIUQguQ65wx4ZUyJKjJmlUoyWwDxi7EwAUoavUldlxl33S4m0ocbGZNLtUtQu_RqlxcBerVa821ZZOO_0l23HStJVyDbD1TTM1n7m1QKc5wbwjgmlLE0J6LgMKgZdzXSeICeus2UrgRG6c7YnOWL2Uz2j07lLpDW1OenrhP6PGwJPa-FbAU_VOf1vQZQlyut1ZLcaUmCI-v2dGNYsvEDiYE8AGcHohugJ6tpt9IdjitNtfAyLhMP1C9A95d2uFJOY84B4i0LbWmvPVOOv_oy45wTSlPy8NrvfIS2sXOeBEcJ3UEb8-nCPAaKNlcdtM5HHJ5ZL-mgze7e4adhx__d0fEeCc9h98sfHxY29g |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFB5qBRVEtN6iVaMoKhKazCQzGUGktpZd222hbsu-DZlbDWyTuhcX_U_-R8_ksjaIfevbMnMmbM6cyzeZc0HopYlVwqwiAeOSB7HNwkC6ZJ_YAJJjWNJUudzhwT7tHcVfRsloBf1uc2FcWGVrEytDrUvlvpFvYLCiAF7A4388-x64rlHudrVtoVGLxa75uYAj2_RDfxv29xXGO5-HW72g6SoQKMrZLKAhSavrMEk5uCfDJKDyBFurOJY6kTzlMBhZrMGTKRUapjGD17GakygLCTz2CroKfjd0CsVGy_NdBM6Wt3k5Kd2YgulnPHDnM0AZPA0WHd9XtQj41xGc84TdKM1zbm_nNrrV4FV_sxawO2jFFGvo2qC5kV9DN-vvfn6dznQX9etyyH5pYY3MdTn23xyd5tYU5Y988tYvC3_r4Li_HUT8vZ_54Cl1eZr_MtpvgubH8LNqJXIPDS-DsffRalEW5iHy4ZiTqYxRwK5hTKROqZUySq0GcBlibjwUtXwUqill7jpqjEV1pEmpqHkvgPei4r1YeOjdcs1ZXcjjQupPbnuWlK4IdzVQTk5Eo9NCSsxwZghlmMSUJhnhmsGgoszVYWMeeuE2V7gyG4WL4znJ5tOp6B8ci00Axkl1B_Y_oq-HHaLXDZEt4UVV1uROALtc-a4O5XqHEoyF6k63giYaYzUVf1XLQ8-X026lC8ArTDmvaNxtP8BLDz2o5XLJHEIAhMY08hDrSGyHe92ZIv9WlTJnjMRxQh5d_Leeoeu94WBP7PX3dx-jG9ipVISDKF5Hq7PJ3DwBXDiTTytt9JG4ZO3_A33jbps |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Arbidol+%28Umifenovir%29+on+COVID-19%3A+a+randomized+controlled+trial&rft.jtitle=BMC+infectious+diseases&rft.au=Nojomi%2C+Marzieh&rft.au=Yassin%2C+Zeynab&rft.au=Keyvani%2C+Hossein&rft.au=Makiani%2C+Mahin+Jamshidi&rft.date=2020-12-14&rft.eissn=1471-2334&rft.volume=20&rft.issue=1&rft.spage=954&rft_id=info:doi/10.1186%2Fs12879-020-05698-w&rft_id=info%3Apmid%2F33317461&rft.externalDocID=33317461 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |